Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2020

01-12-2020 | Vulgar Psoriasis | Commentary

Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy

Authors: Zoe Apalla, Vincent Sibaud

Published in: Supportive Care in Cancer | Issue 12/2020

Login to get access

Excerpt

The introduction of immune checkpoint inhibitors as a treatment modality in advanced malignancies has revolutionized the field of oncology therapeutics. Immunotherapy-mediated adverse events (irAEs) represent a major drawback of their use. Dermatologic AE are among the most common irAEs, reported in about one-third of all treated patients [1]. …
Appendix
Available only for authorised users
Literature
1.
Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 19:345–361CrossRef
2.
3.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, in collaboration with the National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714–1768CrossRef
4.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME (2019) Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol 37:2746–2758CrossRef
5.
Tattersall IW, Leventhal JS (2020) Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med 93:123–132PubMedPubMedCentral
6.
Bhor U, Pande S (2006) Scoring systems in dermatology. J Dermatol Venereol Leprol 72:315–321CrossRef
7.
Amatore F, Villani A-P, Tauber M, Viguier M, Guillot B, the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie) (2019) French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 33:464–483CrossRef
8.
Metadata
Title
Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy
Authors
Zoe Apalla
Vincent Sibaud
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05701-9

Other articles of this Issue 12/2020

Supportive Care in Cancer 12/2020 Go to the issue

Letter to the Editor

Response to the letter to the Editor concerning manuscript entitled, “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide”

Review Article

Patient and carer experience of nutrition care throughout treatment for head and neck cancer: a systematic qualitative review and thematic synthesis

Original Article

Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy

Original Article

Clinical outcomes and prognostic factors associated with internal ureteral stent placement for malignant extrinsic ureteral obstruction

Original Article

Changes in hunger among pediatric patients with cancer and hematopoietic stem cell transplantation recipients

Review Article

Financial toxicity and employment status in cancer survivors. A systematic literature review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits